An innovative radiation hardened CAM architecture

Autor: Anagnostou, O., Liberali, V., Mews, M., Shojaii, S.

Publikováno v: In Nuclear Inst. and Methods in Physics Research, A 21 August 2019 936:288-289

Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response:a sub-study of the NEAT001/ANRS143 randomized trial

Autor: Dickinson L., Gurjar R., Stohr W., Bonora S., Owen A., D'Avolio A., Cursley A., Molina J. -M., Faetkenheuer G., Vandekerckhove L., Di Perri G., Pozniak A., Richert L., Raffi F., Boffito M., Dedes N., Chene G., Allavena C., Autran B., Antinori A., Bucciardini R., Vella S., Horban A., Arribas J., Babiker A. G., Pillay D., Franquet X., Schwarze S., Grarup J., Fischer A., Wallet C., Diallo A., Saillard J., Moecklinghoff C., Stellbrink H. -J., Vanleeuwen R., Gatell J., Sandstrom E., Flepp M., Ewings F., George E. C., Hudson F., Pearce G., Quercia R., Rogatto F., Leavitt R., Nguyen B. -Y., Peto T., Goebel F., Marcotullio S., Miller V., Sasieni P., Arnault F., Boucherie C., Jean D., Paniego V., Paraina F., Rouch E., Schwimmer C., Soussi M., Taieb A., Termote M., Touzeau G., Babiker A., Dodds W., Hoppe A., Kummeling I., Pacciarini F., Paton N., Russell C., Taylor K., Ward D., Aagaard B., Eid M., Gey D., Gramjensen B., Jakobsen M. -L., Jansson P. O., Jensen K., Mariajoensen Z., Moseholmlarsen E., Pahl C., Pearson M., Nielsen B. R., Reilev So. S., Christ I., Lathouwers D., Manting C., Van Leeuwen R., Mendy B., Metro A., Couffin-Cadiergues S., Knellwolf A. -L., Palmisiano L., Aznar E., Barea C., Cotarelo M., Esteban H., Girbau I., Moyano B., Ramirez M., Saiz C., Sanchez I., Yllescas M., Binelli A., Colasanti V., Massella M., Anagnostou O., Gioukari V., Touloumi G., Schmied B., Rieger A., Vetter N., Dewit S., Florence E., Gerstoft J., Mathiesen L., Katlama C., Cabie A., Cheret A., Dupon M., Ghosn J., Girard P. -M., Goujard C., Levy Y., Morlat P., Neau D., Obadia M., Perre P., Piroth L., Reynes J., Tattevin P., Ragnaud J. M., Weiss L., Yazdan Y., Yeni P., Zucman D., Esser S., Fatkenheuer G., Hoffmann C., Jessen H., Rockstroh J., Schmidt R., Stephan C., Unger S., Hatzakis A., Daikos G. L., Papadopoulos A., Skoutelis A., Banhegyi D., Mallon P., Mulcahy F., Andreoni M., Castelli F., D'Arminiomonforte A., Diperri G., Galli M., Lazzarin A., Mazzotta F., Torti C., Vullo V., Prins J., Richter C., Verhagen D., Vaneeden A., Doroana M., Antunes F., Maltez F., Sarmento-Castro R., Gonzalez Garcia J., Aldeguer J. L., Clotet B., Domingo P., Gatell J. M., Knobel H., Marquez M., Pilarmiralles M., Portilla J., Soriano V., Tellez M., Thalme A., Blaxhult A., Gisslen M., Winston A., Fox J., Gompels M., Herieka E., Johnson M., Leen C., Teague A., Williams I., Boyd M., Moller N. F., Moseholmlarsen E. F., Lemoing V., Wit F. W. N. M., Kowalska J., Berenguer J., Moreno S., Muller N. J., Torok E., Post F., Angus B., Calvez V., Boucher C., Collins S., Dunn D., Lambert S., Marcelin A. -G., Perno C. F., White E., Ammassari A., Schmidt R. E., Odermarsky M., Smith C., Thiebaut R., Delaserna J. I. B., Castagna A., De Wit S., Furrer H. -J., Mocroft A., Reiss P., Fragola V., Lauriola M., Murri R., Nieuwkerk P., Spire B., Volny-Anne A., West B., Amieva H., Llibre Codina J., Braggion M., Foca E.

Publikováno v: Dickinson, L, Gurjar, R, Stöhr, W, Bonora, S, Owen, A, D'Avolio, A, Cursley, A, Molina, J-M, Fäetkenheuer, G, Vandekerckhove, L, Di Perri, G, Pozniak, A, Richert, L, Raffi, F, Boffito, M, NEAT001/ANRS143 Study Group, Dedes, N, Chene, G, Richert, L, Grarup, J, Aagaard, B, Eid, M, Gey, D, Jensen, B G, Grarup, J, Jakobsen, M L, Jansson, P O, Jensen, K, Joensen, Z M, Larsen, E M, Pahl, C, Pearson, M, Nielsen, B R, Reilev, S S, Gerstoft, J, Mathiesen, L, Friis-Møller, N & Larsen, E F M 2020, ' Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response : a sub-study of the NEAT001/ANRS143 randomized trial ', Journal of Antimicrobial Chemotherapy, vol. 75, pp. 628-639 . https://doi.org/10.1093/jac/dkz479
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Journal of antimicrobial chemotherapy, 75(3), 628-639. Oxford University Press

Objectives NEAT001/ANRS143 demonstrated non-inferiority of once-daily darunavir/ritonavir (800/100 mg) + twice-daily raltegravir (400 mg) versus darunavir/ritonavir + tenofovir disoproxil fumarate/emtricitabine (245/200 mg once daily) in treatment-na

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3dbe53a0b53bf6926498ee438b2c6427
https://curis.ku.dk/ws/files/290397175/Stohr_Population_pharmacokinetics_and_pharmacogenetics_of_ritonavir_boosted_darunavir_accepted_version_.pdf

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Aiming towards hepatitis C virus elimination in Greece

Autor: Papatheodoridis, G.V. Goulis, J. Sypsa, V. Lionis, C. Manolakopoulos, S. Elefsiniotis, I. Anagnostou, O. Tsoulas, C. Hatzakis, A. Dalekos, G.N.

There are estimated to be 74,000-134,000 patients living with chronic hepatitis C in Greece, but only 20-30% of them are aware of their disease status. In July 2017, the Hellenic National Plan for Hepatitis C was announced in alignment with the World

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::ae27415d3f3cee98518c77cb8934f252
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3106504

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.